2017 Fiscal Year Final Research Report
Treatment strategy for kidney disease based on TLR4-macrophage control by alfa1-acid glycoprotein
| Project/Area Number |
16K15320
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小田切 優樹 崇城大学, 薬学部, 教授 (80120145)
丸山 徹 熊本大学, 薬学部, 教授 (90423657)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | alfa1-acid glycoprotein / kidney disease / TLR4 / macrophage |
|---|
| Outline of Final Research Achievements |
Human alfa1-acid glycoprotein (AGP) is known as an acute phase reactant, and we have recently found anti-inflammatory effects of AGP. In this study, the effect of AGP on renal protection on adriamycin-nephropathy (AN) mice was investigated. As a result, administration of AGP to AN mice reduced proteinuria and improved kidney tissue inury. At that time, the expression level of TNF-alfa and macrophage marker F4/80 in the kidney was decreased. Addition of AGP to macrophages resulted in an increase in IL-10 production and a decrease in iNOS expression. At the same time, gene expression of CD 163 also increased. In conclusion, we discovered for the first time that AGP exerts a renoprotective effect through the calming of the inflammatory response caused by macrophages.
|
| Free Research Field |
医療薬学
|
